BMP2 and breast carcinoma: In addition, using our breast cancer MCF10A-derived BMP2-driven early transformation model or primary non-tumoral tissues from BRCA-mutated carriers, we established that the ENI10 is a powerful tool to identify very early transformation processes, further confirmed in the context of melanoma in which CD10 has been associated with aggressiveness and treatment escape (58).